Abstract
Several TNF antagonists, mainly monoclonal antibodies, have shown to be efficacious in the therapy of Crohns disease. Despite the fact that they have been used for over a decade, their precise mechanism of action is still a matter of investigation. The effects of anti-TNF agents are mediated by multiple mechanisms including direct neutralization of soluble TNF and interaction with membrane-bound TNF. Anti-TNF agents may act by reduction of proinflammatory cytokine levels, elimination or clearance of active inflammatory cells from inflamed tissue which can conceptually be achieved by a number of mechanisms including apoptosis induction, antibody and complement mediated cytotoxicity and inhibition of cell migration into the intestinal tissue. Regulatory events both in the cellular and intracellular levels probably play a role as well. Finally, effects of anti-TNF agents may vary according to their physical contact with TNF leading to different binding avidities, conformational changes and variable downstream effects. These effects may also be influenced by structural differences in the non-TNF binding domain which affects the ability of each drug to interact with the immune system. Our understanding of these mechanisms of action is limited by the fact that much of the data was obtained using artificial in vitro systems of which their relevance to the in vivo situation is uncertain.
Keywords: Anti-TNFantibodies, soluble TNF, membrane TNF, inflammatory cells, apoptosis, cytokines
Current Drug Targets
Title: Efficacy of Anti-TNF in Crohns Disease: How Does it Work?
Volume: 11 Issue: 2
Author(s): Yehuda Chowers and Matthieu Allez
Affiliation:
Keywords: Anti-TNFantibodies, soluble TNF, membrane TNF, inflammatory cells, apoptosis, cytokines
Abstract: Several TNF antagonists, mainly monoclonal antibodies, have shown to be efficacious in the therapy of Crohns disease. Despite the fact that they have been used for over a decade, their precise mechanism of action is still a matter of investigation. The effects of anti-TNF agents are mediated by multiple mechanisms including direct neutralization of soluble TNF and interaction with membrane-bound TNF. Anti-TNF agents may act by reduction of proinflammatory cytokine levels, elimination or clearance of active inflammatory cells from inflamed tissue which can conceptually be achieved by a number of mechanisms including apoptosis induction, antibody and complement mediated cytotoxicity and inhibition of cell migration into the intestinal tissue. Regulatory events both in the cellular and intracellular levels probably play a role as well. Finally, effects of anti-TNF agents may vary according to their physical contact with TNF leading to different binding avidities, conformational changes and variable downstream effects. These effects may also be influenced by structural differences in the non-TNF binding domain which affects the ability of each drug to interact with the immune system. Our understanding of these mechanisms of action is limited by the fact that much of the data was obtained using artificial in vitro systems of which their relevance to the in vivo situation is uncertain.
Export Options
About this article
Cite this article as:
Chowers Yehuda and Allez Matthieu, Efficacy of Anti-TNF in Crohns Disease: How Does it Work?, Current Drug Targets 2010; 11 (2) . https://dx.doi.org/10.2174/138945010790309876
DOI https://dx.doi.org/10.2174/138945010790309876 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Anti-inflammatory Sulfur-Containing Agents with Additional Modes of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Growth Factors and Platelet Rich Plasma in Anterior Cruciate Ligament Reconstruction
Current Stem Cell Research & Therapy Physical Function and Exercise in Older Patients with Cardiovascular and Respiratory Conditions
Current Pharmaceutical Design Mechanistic Approach to Understanding Psychosis Risk in Velocardiofacial Syndrome
Current Pediatric Reviews The Chemistry of Anti-HCV Nucleosides and Pro-Nucleotides
Current Organic Synthesis Tumor Necrosis Factor Inhibitors from Poxviruses with An Emphasis on Tanapoxvirus-2L Protein
Recent Patents on DNA & Gene Sequences Highly Selective Phosphodiesterase 4 Inhibitors for the Treatment of Allergic Skin Diseases and Psoriasis
Inflammation & Allergy - Drug Targets (Discontinued) Alogliptin: a Novel Molecule for Improving Glycemic Control in Type II Diabetes Mellitus
Current Diabetes Reviews Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Immunotherapeutic Approaches in MS: Update on Pathophysiology and Emerging Agents or Strategies 2006
Endocrine, Metabolic & Immune Disorders - Drug Targets Perfusion Computed Tomography and its Application in Oncologic Practice
Current Molecular Imaging (Discontinued) subject Index To Volume 1
Current Drug Targets - Infectious Disorders The Congenital Cytomegalovirus Infection: Virus-Host Interaction for Defense and Transmission
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Mechanisms of Cell Death: Biomedical Implications (Executive Editor: E. Ottaviani)]
Current Pharmaceutical Design Compacting Proteins: Pros and Cons of Osmolyte-Induced Folding
Current Protein & Peptide Science Rapid Desensitization of Hypersensitivity Reactions to Chemotherapy Agents.
Current Drug Safety Biological Aspects and Clinical Applications of Mesenchymal Stem Cells: Key Features You Need to be Aware of
Current Pharmaceutical Biotechnology Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology Biomarkers of Immunity and Inflammation for use in Nutrition Interventions: International Life Sciences Institute European Branch Work on Selection Criteria and Interpretation
Endocrine, Metabolic & Immune Disorders - Drug Targets